Our findings support the notion that the viral Bcl-2 homologue E1B19K should be deleted in oncolytic adenoviruses to attain maximal efficacy in combination with current clinical therapies and that expression of Bcl-2 supports the propagation of these mutants in tumour cells. The gene discussed is BCL2; the disease is neoplasm.